17
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Serum aminoterminal propeptide of type III procollagen (S-PIIINP) and hepatobiliary dysfunction in patients with ulcerative colitis

, , , , &
Pages 297-305 | Received 04 Jul 1996, Accepted 10 Mar 1997, Published online: 05 Aug 2009
 

Abstract

The aim of the study was to estimate the usefulness of measuring the circulating concentration of serum aminoterminal propeptide of type III collagen (S-PIIINP) in screening for hepatobiliary diseases in patients with ulcerative colitis. S-PIIINP was measured in 69 patients with ulcerative colitis and normal liver biochemistry, in 14 patients with ulcerative colitis and elevated catalytic concentration of alkaline phosphatases in serum (S-ALP, EC 3.1.3.1) but without primary sclerosing cholangitis (PSC), and in 20 patients with ulcerative colitis and PSC. The median S-PIIINP was 3.1 μg 1−1 in patients with ulcerative colitis and normal liver biochemistry, 4.3 μg 1−1 in patients with ulcerative colitis and hepatobiliary disorder other than PSC and 8.9 μg 1−1 in those with ulcerative colitis and PSC. When the S-PIIINP cut-off level was set at 5.0 μg1−1, 1% of the patients with ulcerative colitis and normal liver biochemistry, 21% of those with hepatobiliary disorder, not PSC, and 90% of the patients with PSC had S-PIIINP values above that concentration. In conclusion, S-PIIINP above 5.0 μg 1−1 in a patient with ulcerative colitis strongly suggests concomitant PSC.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.